Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
ImpediMed Limited (IPD.AX)
AUD0.01
+0.00 (+20.00%)
AU ASX Healthcare Medical - Devices
Address
50 Parker Court 4008
Pinkenba, QLD, AU
Pinkenba, QLD, AU
CEO
Erik Anderson
Website
impedimed.com
IPO
2007-10-24
ISIN AU000000IPD8
Also trades on
Australian Securities Exchange · IPD.AX (AUD)
Other OTC · IPDQF (USD)
Description
Operating as a medical software technology provider, ImpediMed Limited is responsible for the development, production, and global sales of bioimpedance spectroscopy (BIS) instruments and accompanying software solutions, serving markets in Australia, North America, and internationally. Its product portfolio features SOZO, a non-invasive BIS device used for evaluating lymphedema and tracking fluid levels in heart failure patients. Additionally, it offers the SFB7, a single-channel, tetrapolar BIS instrument for analyzing body composition in healthy individuals, and ImpediVET, another single-channel, tetrapolar BIS device specifically designed for veterinary applications to measure fluid status and tissue composition. ImpediMed primarily sells its technology to hospitals and clinics. This Australian-headquartered firm, based in Pinkenba, was established in 1999.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
AUD0.01
+0.00 (+20.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
8M
Beta
1.10
Float Shares
1.84B
Free Float %
90.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +16.67% | +0.00% | -50.00% | -58.82% | -81.58% | -79.41% | -76.67% | -95.00% | -94.62% | -99.23% | -99.09% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.01
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 4 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-15.51
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%+23.3% ★ Q4'25: +57.1% (vs Q4'23)
-
EPS growth Medical - Devices: +28.5%-15.0% Q4'25: -22.4% (vs Q4'23)
-
FCF margin FCF growth · Medical - Devices: +30.9%-154.5% Q4'25: +0.0% (vs Q4'23)
-
EBIT margin Medical - Devices: +6.2%-173.8% Q4'25: -127.9% (vs Q4'23)
-
ROIC Medical - Devices: +3.3%-172.7% Q4'25: -301.5% (vs Q4'23)
-
Share dilution Medical - Devices: 0.0%-0.1% ★ Q4'25: -16.3% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-0.83× Q4'25: -0.73× (vs Q4'23)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Jun 2008 actual |
Jun 2009 actual |
Jun 2010 actual |
Jun 2011 actual |
Jun 2012 actual |
Jun 2013 actual |
Jun 2014 actual |
Jun 2015 actual |
Jun 2016 actual |
Jun 2017 actual |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 2 Rev. Ana. 3 EPS Ana. |
Jun 2027 3 Rev. Ana. 4 EPS Ana. |
Jun 2028 3 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.31M
est: 3.04M (-24.1%)
|
2.99M
est: 3.48M (-14.0%)
|
3.64M
est: 3.89M (-6.5%)
|
3.89M
est: 4.11M (-5.4%)
|
2.95M
est: 2.68M (+9.8%)
|
2.73M
est: 2.53M (+8.0%)
|
3.52M
est: 3.34M (+5.5%)
|
4.84M
est: 4.54M (+6.6%)
|
5.79M
est: 6.20M (-6.6%)
|
5.77M
est: 7.09M (-18.6%)
|
3.32M
est: 6.68M (-50.3%)
|
4.16M
est: 4.20M (-1.1%)
|
5.74M
est: 6.35M (-9.6%)
|
8.41M
est: 10.20M (-17.6%)
|
10.57M
est: 10.00M (+5.7%)
|
11.34M
est: 12.39M (-8.4%)
|
10.32M
est: 10.30M (+0.2%)
|
12.72M
est: 14.53M (-12.4%)
|
15.57M
15.36M – 15.78M
+7.1% YoY
|
21.60M
20.92M – 22.95M
+38.8% YoY
|
31.10M
30.36M – 32.40M
+44.0% YoY
|
| EBITDA |
-7.71M
est: -3.04M (-153.2%)
|
-13.25M
est: -13.09M (-1.2%)
|
-10.66M
est: -15.70M (+32.1%)
|
-14.14M
est: -12.04M (-17.5%)
|
-12.89M
est: -9.68M (-33.1%)
|
-9.24M
est: -11.64M (+20.6%)
|
-7.84M
est: -11.15M (+29.7%)
|
-14.97M
est: -10.71M (-39.8%)
|
-26.00M
est: -21.33M (-21.9%)
|
-30.52M
est: -29.67M (-2.9%)
|
-30.35M
est: -22.73M (-33.5%)
|
-26.33M
est: -22.78M (-15.6%)
|
-24.07M
est: -33.87M (+28.9%)
|
-20.70M
est: -33.15M (+37.5%)
|
-18.65M
est: -64.75M (+71.2%)
|
-20.49M
est: -103.44M (+80.2%)
|
-22.05M
est: -188.06M (+88.3%)
|
-17.55M
est: -370.12M (+95.3%)
|
-15.57M
-15.78M – -15.36M
+95.8% YoY
|
-21.60M
-22.95M – -20.92M
-38.8% YoY
|
-31.10M
-32.40M – -30.36M
-44.0% YoY
|
| EBIT |
-8.07M
est: -3.04M (-164.9%)
|
-14.02M
est: -9.23M (-52.0%)
|
-11.40M
est: -15.67M (+27.3%)
|
-14.81M
est: -12.04M (-23.0%)
|
-13.47M
est: -9.67M (-39.2%)
|
-9.50M
est: -11.64M (+18.4%)
|
-8.00M
est: -11.15M (+28.2%)
|
-15.15M
est: -10.71M (-41.4%)
|
-28.33M
est: -21.33M (-32.8%)
|
-30.75M
est: -29.67M (-3.7%)
|
-30.64M
est: -22.73M (-34.8%)
|
-27.01M
est: -22.68M (-19.1%)
|
-25.56M
est: -33.69M (+24.1%)
|
-23.07M
est: -33.15M (+30.4%)
|
-21.54M
est: -64.75M (+66.7%)
|
-22.99M
est: -103.44M (+77.8%)
|
-24.30M
est: -188.06M (+87.1%)
|
-22.12M
est: -370.12M (+94.0%)
|
-15.57M
-15.78M – -15.36M
+95.8% YoY
|
-21.60M
-22.95M – -20.92M
-38.8% YoY
|
-31.10M
-32.40M – -30.36M
-44.0% YoY
|
| Net Income |
-9.75M
est: -220.59M (+95.6%)
|
-14.03M
est: -11.16M (-25.7%)
|
-11.40M
est: -15.68M (+27.3%)
|
-14.82M
est: -12.04M (-23.1%)
|
-12.34M
est: -9.68M (-27.5%)
|
-8.46M
est: -11.64M (+27.3%)
|
-7.94M
est: -11.15M (+28.8%)
|
-14.80M
est: -10.71M (-38.2%)
|
-25.98M
est: -21.33M (-21.8%)
|
-27.57M
est: -29.67M (+7.1%)
|
-27.25M
est: -22.76M (-19.7%)
|
-24.00M
est: -22.82M (-5.2%)
|
-21.38M
est: -33.94M (+37.0%)
|
-20.71M
est: -33.22M (+37.7%)
|
-19.87M
est: -64.90M (+69.4%)
|
-20.52M
est: -20.52M (+0.0%)
|
-19.79M
est: -19.79M (+0.0%)
|
-23.24M
est: -23.24M (+0.0%)
|
-13.78M
-17.57M – -9.98M
+40.7% YoY
|
-7.59M
-12.21M – -2.97M
+44.9% YoY
|
-2.72M
-2.84M – -2.61M
+64.1% YoY
|
| SGA |
5.08M
est: 6.30M (-19.5%)
|
7.12M
est: 7.21M (-1.2%)
|
8.17M
est: 8.06M (+1.4%)
|
11.87M
est: 8.51M (+39.5%)
|
8.39M
est: 5.55M (+51.1%)
|
8.14M
est: 5.24M (+55.3%)
|
10.05M
est: 6.91M (+45.5%)
|
13.70M
est: 9.41M (+45.6%)
|
20.23M
est: 12.84M (+57.6%)
|
23.39M
est: 14.67M (+59.4%)
|
29.67M
est: 13.83M (+114.6%)
|
21.36M
est: 8.70M (+145.5%)
|
20.97M
est: 13.15M (+59.5%)
|
22.97M
est: 21.12M (+8.8%)
|
20.23M
est: 20.70M (-2.3%)
|
19.96M
est: 25.65M (-22.2%)
|
22.62M
est: 21.32M (+6.1%)
|
22.31M
est: 30.09M (-25.8%)
|
32.23M
31.79M – 32.66M
+7.1% YoY
|
44.72M
43.32M – 47.52M
+38.8% YoY
|
64.39M
62.85M – 67.08M
+44.0% YoY
|
| EPS |
-0.13
est: -0.11 (-19.0%)
|
-0.15
est: -0.13 (-16.0%)
|
-0.09
est: -0.10 (+2.8%)
|
-0.09
est: -0.08 (-10.7%)
|
-0.07
est: -0.07 (-10.0%)
|
-0.04
est: -0.04 (+1.5%)
|
-0.04
est: -0.03 (-45.2%)
|
-0.05
est: -0.04 (-44.3%)
|
-0.08
est: -0.06 (-18.8%)
|
-0.07
est: -0.07 (+2.0%)
|
-0.07
est: -0.06 (-5.5%)
|
-0.06
est: -0.05 (-15.8%)
|
-0.04
est: -0.04 (+12.4%)
|
-0.02
est: -0.02 (-1.2%)
|
-0.01
est: -0.01 (+12.6%)
|
-0.01
est: -0.01 (-3.6%)
|
-0.01
est: -0.01 (+3.2%)
|
-0.01
est: -0.01 (-35.3%)
|
-0.01
-0.01 – 0.00
+17.6% YoY
|
0.00
-0.01 – 0.00
+57.1% YoY
|
0.00
0.00 – 0.00
+55.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-27.26M
OE per share TTM
-0.01
Owner's Yield
-191.44%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
11.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
1
Total invested
207.00
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
1
+0 vs prev Q
New positions
0
Closed positions
0
Increased
0
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | NORTH STAR ASSET MANAGEMENT INC | 20.0K +— (+0.0%) | 454.00 -35.0 (-7.2%) | 0.00% +0.000 pp | 0.00% +0.000 pp | AUD0.15 -80.0% | 16 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-266.5K
Shares Outstanding
2.04B
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Parmjot Bains | MD, Chief Executive Officer & Director | 490.0K | — |
| McGregor Grant FCIS GAICD | Chief Financial Officer & Executive Director | 430.0K | male |
| Julie Kuhlken | Senior Director of Marketing | — | female |
| Leanne Ralph AAICD ACIS | Company Secretary | — | female |
| Scott Long | Senior Vice President of US Sales, Key Accounts, & Renewals | — | male |
| Ashley Munoz | Director of Human Resources | — | female |
| Steven Chen | Chief Medical Officer | — | — |
| Erik Anderson | CEO, MD & Director | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IPD.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
